Small molecule · Antagonist of corticotropin-releasing factor type 1 receptor (CRHR1) · developed by Spruce Biosciences
Tildacerfont is an orally bioavailable, selective nonsteroidal antagonist of the corticotropin-releasing factor type 1 (CRF1) receptor in the pituitary gland. By blocking this receptor it reduces ACTH secretion and the overproduction of adrenal androgens. It is studied in congenital adrenal hyperplasia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05128942 | Phase 2 | Congenital Adrenal Hyperplasia | Terminated | SPRB |
| NCT03257462 | Phase 2 | Congenital Adrenal Hyperplasia | Completed | SPRB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
21-OHDCAH - Congenital Adrenal HyperplasiaCongenital Adrenal Hyperplasia
Updated Nov 1, 2026. Something wrong or missing? Report it on the SPRB page.
See SPRB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SPRB catalysts and pipeline →